@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015
|
|
- June Gibson
- 6 years ago
- Views:
Transcription
1 How to Win Physician Collaboration Models for Advancing Access to Lifesaving #EAP2015 Jess B. Rabourn CBI Expanded Access Conference July 22, 2015
2 How to Win Now that we want Expanded Access. How do we launch programs that: Reach a meaningful number of patients Do not interfere with clinical research Benefit all involved parties (Drug Co., HCPs, patients, public)
3 How to Win A New Way Forward Partnerships of Aligned Interests
4 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics +10 min. Q&A
5 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics +10 min. Q&A
6 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics +10 min. Q&A
7 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics +10 min. Q&A
8 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics +10 min. Q&A
9 Why Expanded Access Why is Expanded Access needed? 1938 Food, Drug, & Cosmetic Act (FDCA) Prohibits use of new drugs before approval (interstate commerce) 1962 Kefauver-Harris Amendment to FDCA Requires substantial efficacy evidence before approval One-size-fits all: struggled to differentiate cancer from common cold Investigational New Drug (IND) exemptions for clinical research
10 Post-1962: FDA Gets It! Special exemptions for life-threatening situations Tropical Disease IND Orphan Drug IND Open Label IND Group-C IND Compassionate IND Emergency IND Treatment IND 1987 Promulgation: Expanded Access Treatment IND Emergency IND & Individual IND 1992 FDA / PHS Statement Parallel Track 1990/1997 Devices (HDE / T-IDE) 2009 Final Rule Treatment IND Intermediate-Size IND Emergency IND & Individual IND
11 Post-1962: FDA Gets It! Special exemptions for life-threatening situations Tropical Disease IND Orphan Drug IND Open Label IND Group-C IND Compassionate IND Emergency IND Treatment IND 1987 Promulgation: Expanded Access Treatment IND Emergency IND & Individual IND 1992 FDA / PHS Statement Parallel Track 1990/1997 Devices (HDE / T-IDE) 2009 Final Rule Treatment IND Intermediate-Size IND Emergency IND & Individual IND
12 Post-1962: FDA Gets It! Special exemptions for life-threatening situations Tropical Disease IND Orphan Drug IND Open Label IND Group-C IND Compassionate IND Emergency IND Treatment IND 1987 Promulgation: Expanded Access Treatment IND Emergency IND & Individual IND 1992 FDA / PHS Statement Parallel Track 1990/1997 Devices (HDE / T-IDE) 2009 Final Rule Treatment IND Intermediate-Size IND Emergency IND & Individual IND
13
14
15 Current Access Channels Special exemptions for life-threatening situations Tropical Disease IND Orphan Drug IND Open Label IND Group-C IND Compassionate IND Emergency IND Treatment IND 1987 Promulgation: Expanded Access Treatment IND Emergency IND & Individual IND 1992 FDA / PHS Statement Parallel Track 1990/1997 Devices (HDE / T-IDE) 2009 Final Rule Treatment IND Intermediate-Size IND Emergency IND & Individual IND
16 The Right Channel for the Situation Protocol-Driven Expanded Access Compassionate Use Treatment IND or protocol amendment Intermediate-Size IND or protocol amendment Emergency-Use protocol (For many) Individual Patient IND Emergency Use IND (1-time) For a class or condition affecting more than one patient. Many patients per IND Sponsored by drug company or third party Exceptional / Rare: Bat bite, unexpected reaction / infection, etc. n=1 One patient per IND, handful of patients in total Sponsored by physician Centrally managed and monitored, like research study No central management Standardized dosing, observation, data collection Each MD may write individual protocol, no valuable data
17 Myth and Reality Exploratory Treatment Access FDA Form #1572 or #3926 Exploratory Treatment Access Right To Try Exploratory Treatment Access = Feasible campaign to sponsor and conduct EAP Feasibility = f ( fiscal reward & cost, valuation reward & cost, risk)
18 Myth and Reality Exploratory Treatment Access FDA Form #1572 or #3926 Exploratory Treatment Access Right To Try Exploratory Treatment Access = Feasible campaign to sponsor and conduct EAP Feasibility = f ( fiscal reward & cost, valuation reward & cost, risk)
19 Agenda Intro History / Practice of EA Feasibility Factors Cost Recovery Third Party Model Mechanics + 10min Q&A
20 Feasibility: Drug Company (Sponsor) Hard Costs Supply Chain Regulatory Prep Site Activation, IRB, ICF Protocol, IB, Training Pharmacovigilance, Safety DB Medical Monitoring Public Communication Insurance /Indemnification Coordination Hazards usae E&O / Malpractice Budget Shortfall Public Perception Favoritism Withholding Promotion Profiteering Rewards Engagement / Familiarity Safety Data Research Outcomes Human Mission Elective Costs Cost to Support Sites Research (endpoints, EDC, data) Patient Assistance Funding
21 Feasibility: Health Care Provider Resource Expenditures -IRB / ICF Review -Screening, Enrollment -Pharmacy / Accountability -Administering Product (i.v., peg) -Lab - tox -Medical Evaluation -Record Keeping -Coordination / Training Negotiated Costs For: -Tax for Institution -Margin (Overhead) -Research Endpoints -Data Collection / CRF entry Rewards -More options for treating patients -Familiarity with drug -Learning outcomes (Responder subgroups) -Publication / Visibility Other Considerations -Patient Selection -Informed Consent / Expectations -Safety
22 Feasibility: Determinants 1. Inherited Cost of the product (mfg, finish, storage, shipping) Scale of existing supply process Route of administration (i.v., peg, intrathecal) Safety of the product (monitoring, usaes, regulatory) Prospect for patient benefit 2. Strategic Cost recovery? Research / Endpoint collection? Partnership?
23 Agenda Intro History / Practice of EA Feasibility Factors Cost Recovery Third Party Model Mechanics + 10min Q&A
24 What Costs? What is the total cost of an access program? Product Supply Costs Mfg, finish, labeling, storage, shipping Program Management Costs Regulatory Site activation and monitoring Pharmacovigilance / Reporting Medical monitor Per Site: IRB / ICF Review Record Keeping Training / Coordination Patient Treatment Costs Administration of study drug, observation, lab safety Pharmacy, drug handling and accountability Screening, medical visits Research Costs Endpoint measurement / CRF Imaging, biosample collection Lab analysis Data management / analysis
25 FDA and Cost Recovery Q: What can the sponsor charge to patients or payers? A: Any direct, incremental costs associated with providing study drug. Supply chain costs Central monitoring costs & program mgmt Product Supply Program Mgmt Caveat: No Profit Prior authorization required; annual basis Must not interfere with progress toward market approval 21 CFR (c): Charging for expanded access to investigational drug for treatment use. 21 CFR (d): Costs recoverable when charging for an investigational drug.
26 FDA and Cost Recovery Q: What services can the HCP charge to patients or payers? A: It is up to the HCP and its IRB. FDA authorization is not needed. Patient Treatment Costs Administration of study drug, observation, lab safety Pharmacy, drug handling and accountability Screening, medical visits CFR (c): Charging for expanded access to investigational drug for treatment use. 21 CFR (d): Costs recoverable when charging for an investigational drug.
27 How much is on the sponsor? Simplest, clinical trial model Partnering with HCPs with cost recovery (Kyprolis, ) (Gleevec, ) (Voraxaze, ) Sponsor pays 100% Sponsor pays minimum Patient Treatment Product Supply Product Supply Program Mgmt Program Mgmt Research Research Research
28 How much is on the sponsor? For a SCALABLE-SIZE program, in areas of great unmet need: 1. PARTNERSHIP between Sponsor and HCP. (not vendor / client) 2. Consider recovery of product costs & mgmt costs.
29 Agenda Intro History / Practice of EA Feasibility Factors Cost Recovery Third Party Model Mechanics + 10min Q&A
30 Sponsoring an EAP The Sponsor of an EAP is responsible for: Regulatory Filing Procurement of Investigational Product Medical Monitoring and Reporting Site Selection and Clinical Operations
31 A Platform for Exploratory Medicine in ALS ALS Emergency Treatment Fund (ALS-ETF), a 501c3 non-profit corporation Founded in 2012 with help from patients and patient advocates Created to work in partnership with drug companies, leading disease foundations, and participating clinics Project budget for EAP management, infrastructure, patient assistance fund. *Learning From Patients* initiative for predictive marker discovery, using outcomes data from interventional studies and matching biosamples Network of bioassay and informatics vendors EAPs to provide valuable additional patient data
32 A Third Party Sponsor is Better ALS Emergency Treatment Fund (ALS-ETF): Specialist in Expanded Access Strong Connections in the Medical Community Structurally Aligned with Patients and their Doctors Research Overlay to Generate Valuable Data Large EAPs = Large n marker-discovery trials, in cohorts that are more representational of disease population.
33 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics + 10min Q&A
34 ALS-ETF Case View A Collaboration with HCPs for an Expanded Access Program in ALS Sponsor = ALS-ETF, under agreement with drug company. Medical Advisory Board Steering Committee ( as DSMB)
35 ALS-ETF Case View Program Synopsis: Monthly regimen (i.v. infusion, outpatient) Ongoing treatment (chronic / renewable period) Monthly / Quarterly medical evaluation 1 clinical endpoint + 1 spirometry measure Baseline and 6month blood-sample ********************************************** 100 patients in U.S. program 5-10 sites (5-20 patients at each site) Enrollment: Fixed number for each site By physician; 1 st come 1 st served (No random selection) Subject to inclusion/exclusion criteria
36 This is NOT funded research Drug Product and Materials: Provided to site at no charge HCP s expense for coordination / data entry / record keeping: $10k - $50k subsidy for each site IRB fees, study team fees, site fees: waived Patient Treatment Costs Recovered by HCP from payers / patients
37 ALS-ETF Case View 1. Neither party extracts profit margin 2. Product and grant subsidy to HCP 3. Patient transacts ONLY with HCP 4. HCP recovers its own per-patient treatment cost = Feasibility & Scalability
38 Who pays for patients treatment? Patient Treatment 1. Absorbed by HCP 2. Medicare Part B 3. Private Health Insurance 4. Patient / Patient Assistance
39 Who pays for patients treatment? Default Case: Billing patients Many HCP services are ineligible for reimbursement Charging just for treatment services, not product ALS-ETF negotiates low rate, close to breakeven Patient Assistance Fund via means test (xfpl) Collaboration: Sponsor agrees with sites on billing practice.
40 Who pays for patients treatment? Billing CMS and private insurance: Medicare Part B analysis; National Coverage Determination Protocol-specific, Region-specific Private payer: Special pre-authorization required Policy language on situations of need Standard of Care vs. Research Collaboration: Sponsor and site support NCD Coverage Analysis; Negotiation with private payers led by sponsor and clinic consortium.
41 The Research vs. Care Trap Institution Funding Office Research Unit EAP Sponsor Specialty Clinic Hospital Svc s
42 Sponsor s Cost Recovery? Product Supply Program Mgmt 1. Patient / Patient Assistance Direct Txn between patient and sponsor? Or, bill through clinic? Add on to medical billing. Order management tie-in with A/P, A/R. 2. Traditional Payers Very difficult; involve patient advocacy / lobby
43 Industry / HCP Collaboration Work together to write institutional policies for humanitarian, protocol-driven access programs. i.e. NOT funded research! Choose sites who will bill out for their treatment services. Also, consider cost recovery for product and central management. Work with medical community and with advocacy to improve reimbursement landscape. Third Party Platform as sponsor Specialist, more efficient Better negotiating position Community resources available Shields company from financial / operational burden
44 Agenda Intro History / Practice Feasibility Factors Cost Recovery Third Party Model Mechanics + 10min Q&A
Expanded Access (including Emergency Use & Humanitarian Use Devices)
Expanded Access (including Emergency Use & Humanitarian Use Devices) Bertha delanda, CIP IRB Training Specialist Research Compliance Office March 2012 What Is Expanded Access? Permits use of an investigational
More informationExpanded Access to Investigational Imaging Drugs
Expanded Access to Investigational Imaging Drugs Phillip B. Davis, MD FDA/CDER/ODEIV/DMIP 6/09/2016 1 Overview Expanded Access (EA) Defined Requirements for all EA authorizations Types of EA Individual
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More informationStreamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationClinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally
Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Cerus Corporation Concord, CA Laurence Corash, MD Chief Medical Officer Meisa Propst, Associate Director Clinical
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More informationGuidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationWhat We Learned Running Investigator Initiated Trials
What We Learned Running Investigator Initiated Trials James D. Lewis, MD, MSCE Division of Gastroenterology Center for Clinical Epidemiology & Biostatistics University of Pennsylvania Hans Herfarth, MD,
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationMedical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs
Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Thursday, March 10, 2016 1:00 2:30 EST 12:00 1:30 CST 11:00 12:30 MST 10:00 11:30 PST Casandra Stockman,
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationUS FDA: CMC Issues for INDs
ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More informationA High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges
A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical
More informationPFF DISEASE EDUCATION WEBINAR SERIES. Welcome!
PFF DISEASE EDUCATION WEBINAR SERIES Welcome! PFF DISEASE EDUCATION WEBINAR SERIES David J. Lederer, MD, MS PFF Senior Medical Advisor, Patient Communications Harold Collard, MD PFF Medical Advisory Board
More informationDesigning a Disease-Specific Master Protocol
Designing a Disease-Specific Master Protocol Lisa M. LaVange, PhD Director, Office of Biostatistics OTS/CDER/FDA Pediatric Master Protocols Workshop September 23, 2016 FDA, White Oak Campus Acknowledgments
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationReimbursement Strategy for Companion Diagnostics:
Reimbursement Strategy for Companion Diagnostics: Emerging Models and Requirements Edward E. Berger, Ph.D. Larchmont Strategic Advisors Definition Companion diagnostic A diagnostic test used to predict
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationIndividual Patient and Emergency Use of Drugs: Past, Present, and Right to Try September 30, 2015
Webinar Series Expanded Access/Compassionate Use Part 1 Individual Patient and Emergency Use of Drugs: Past, Present, and Right to Try September 30, 2015 Presented by: Rebecca Carson Rogers, MA, CIP, CHRC
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationThe Future of HealthCare Information Technology
HST.921 / HST.922 Information Technology in the Health Care System of the Future, Spring 2009 Harvard-MIT Division of Health Sciences and Technology Course Directors: Dr. Steven Locke, Dr. Bryan Bergeron,
More informationTHE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE
THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE Ali Mohamadi, M.D. Senior Director, Global Regulatory Patient Engagement and Policy BioMarin Pharmaceutical 30-July-2016 Goals of Today s Presentation
More informationISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research
ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research Pascale Boyer Barresi, CFA Business Analysis, BD&L September 2014
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More information2 : self-directing freedom and especially moral independence 3 : a self-governing state
A Adverse Effect Adverse Event AE Amendment Approve Approve Pending Assent Assurance Authorization Autonomy Unanticipated problem or unfavorable symptom or disease occurring during a clinical study, though
More informationCenter for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.
Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information
More informationSUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
More informationHarmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees
Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities Plus an update on PET Drug User Fees Michael Nazerias - Vice President, RA/QA PETNET Solutions, Inc. (a Siemens Company)
More informationDetermining Patient Access to Investigational Drugs in the US
Determining Patient Access to Investigational Drugs in the US Philip Katz examines the reasons for and against treating terminally ill patients with investigational drugs, focusing on efforts to change
More informationPlanning for Successful Medical Device Reimbursement:
Planning for Successful Medical Device Reimbursement: So Your Device Is Cleared, By Tiffini Diage, MPH Health Economics NAMSA White Paper Key Considerations for Targeting Success of Medical Device Sales
More informationOccupational Health Services As a Practice Opportunity
Occupational Health Services As a Practice Opportunity This appeared in The Alliance For Healthcare Strategy And Marketing s The Alliance Report, September/October 1996 issue. Written by: Meg Flanagan
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationObtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored
More informationHow Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company
How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationINVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version
More informationThe Clinical Research Regulatory Process
The Clinical Research Regulatory Process Understanding the Impact A CenterWatch-Complion Survey by Rick Arlow, Founder and CEO Complion Inc. Introduction The importance of data validity obtained from a
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationThe Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget
The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationThe Drug Development Process and Design of Clinical Trials
The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trial Design Guidance Clinical Trial:
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationFDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of an Individual Patient with an Investigational Drug or a REMS-restricted, Approved Drug Guidelines:
More informationEnd-to-End Management of Clinical Trials Data
End-to-End Management of Clinical Trials Data A Revolutionary Step Toward Supporting Clinical Trials Analysis Over the Next Decades of Clinical Research WHITE PAPER SAS White Paper Table of Contents Introduction....
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationProtection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
More informationThe Research Services Organization (RSO) of the Academic Health Center
Annual Report 2005 The Research Services Organization (RSO) of the Academic Health Center A Summary of the Eighth Year of Operations Submitted by: Mark S. Paller, M.D., M.S. Director, Research Services
More informationExpanded Access A Regulatory Balancing Act For Drug Cos.
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Expanded Access A Regulatory Balancing Act
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationDefinitions and Acronyms
Definitions and Acronyms 510(k) A particular FDA Class For Medical Devices AE Adverse Event CFR Code of Federal Regulations CMS United States Center/College for Medicare and Medicaid Services CRA Clinical
More informationAvailability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for
This document is scheduled to be published in the Federal Register on 06/04/2013 and available online at http://federalregister.gov/a/2013-13083, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationMaintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist
Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit
More informationOff-Label Use of FDA-Approved Drugs and Biologicals
Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationGOOD CLINICAL PRACTICE (GCP) Series Catalog
GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational
More informationCommercial Pricing and Contracting 101
Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai
More informationICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.
ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research
More informationCreating Pre-Patient Relationships through Employer Outreach
Employer Engagement as a Consumer Acquisition Strategy: Creating Pre-Patient Relationships through Employer Outreach Jan Hess Vice President Professional and Administrative Services, St. Luke s Hospital
More informationCTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationUtilizing Innovative Statistical Methods. Discussion Guide
Utilizing Innovative Statistical Methods and Trial Designs in Rare Disease Settings Discussion Guide Background Rare diseases are a complex and diverse set of conditions which, when taken together, affect
More informationPHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14
PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationNew Complexities in Pricing Orphan and Ultra-Orphan Drugs
New Complexities in Pricing Orphan and Ultra-Orphan Drugs September 28, 2010 Agenda Orphan drugs and their prices are less rare Changes in ultra-orphan markets Increased competition Big pharma enters When
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationHealthcare s New Change-Maker: The CFO
The role of hospital chief financial officer has changed dramatically over the last 50 years. No longer simply responsible for managing the hospital s finances, today s CFO is a change agent, an indispensable
More informationIND Exemption, Preparation and Maintenance. Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University
IND Exemption, Preparation and Maintenance Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University 1 Templates and Guidance Best Practices Templates/Instructions http://tiny.cc/d7bpt
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationCalendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule
Calendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule August 2017 This document is presented for informational purposes only and is not intended to provide reimbursement
More informationExperience with Adaptive Dose-Ranging Studies in Early Clinical Development
Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive
More information